Dr. Eugene Shenderov, MD, PhD

Dr. Shenderov practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Shenderov's NPI, 1720358633, was assigned on January 9, 2012. Dr. Shenderov graduated from Johns Hopkins University School of Medicine in 2013. Dr. Shenderov holds Maryland license D81131.

Dr. Shenderov's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Shenderov's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Shenderov is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Shenderov to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shenderov practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Shenderov's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Shenderov is licensed in Maryland.

CMS data shows 89 Medicare services from Dr. Shenderov across 3 procedure codes in 2024, for 48 Medicare patients. Medicare paid $5,787 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 48 Medicare patients who saw Dr. Shenderov in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have high blood pressure, and 73% have cancer. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shenderov's median patient age at 75, with 8% women.

In 2024, Dr. Shenderov wrote 70 Medicare Part D claims. 23% of them were for generic drugs. CMS names the drug for 48 of them, across 1 drug with 11 or more claims each, at $644,683 in total drug cost. In 2023, CMS named 33 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Shenderov for performance year 2024, reported as part of a group. CMS lists Dr. Shenderov as offering telehealth.

Dmand AI links 22 papers to Dr. Shenderov, published from 2012 to 2025. 2024 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms, B7 Antigens and Prostatic Neoplasms, Castration-Resistant. Dr. Shenderov has published most often in Prostate. Dr. Shenderov's most frequent co-authors are Mohamad E. Allaf, MD, Samuel Ray Denmeade, MD and Mario Eisenberger, MD.

Dmand AI links Dr. Shenderov to 1 clinical trial. Conditions studied include Triple Negative Breast Neoplasms and Squamous Cell Carcinoma of Head and Neck. Open Payments lists research payments to Dr. Shenderov that name 1 trial.

CMS Open Payments shows 14 general payments to Dr. Shenderov from 5 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 73% of the total. Sanofi and Genzyme US Companies paid the most, $402. It also lists 3 research payments totaling $12,659 in 2021, naming 1 clinical trial.

Dr. Shenderov graduated from Johns Hopkins University School of Medicine in 2013.